Michael Amoroso is the CEO of Precision BioSciences, a biotechnology company focused on making a positive impact in the healthcare landscape. With an Executive M.B.A. from NYU's Stern School and a B.A. in Biological Sciences, Amoroso brings a robust academic...
Michael Amoroso is the CEO of Precision BioSciences, a biotechnology company focused on making a positive impact in the healthcare landscape. With an Executive M.B.A. from NYU's Stern School and a B.A. in Biological Sciences, Amoroso brings a robust academic foundation to his role. His career includes a stint at Abeona Therapeutics before joining Precision BioSciences in October 2021. Under his leadership, the company's compensation structure focuses on aligning executive pay with company performance, balancing salary and bonuses based on achievement metrics. In 2023, Amoroso's total compensation reached over $1 million, largely influenced by his strategic decisions that have driven the company forward. Notably, he has seen significant fluctuations in his insider trading activities, peaking in early 2024 when he sold shares valued at over $240,000, signaling a confident stance in his company's future. His journey reflects a blend of strategic insight and deep sector expertise, positioning him as a pivotal figure in the biotechnology arena.